Skip to main content
Erschienen in: InFo Hämatologie + Onkologie 11/2021

15.11.2021 | Lymphome | Schwerpunkt

Schwerpunkt "HIV-assoziierte Tumoren"

HIV-assoziierte Lymphome

verfasst von: Prof. Dr. med. Marcus Hentrich

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 11/2021

Einloggen, um Zugang zu erhalten

Auszug

Eine HIV-Infektion erhöht für Patientinnen und Patienten auch das Risiko, an einem malignen Lymphom zu erkranken. Um welche Lymphome es sich handelt und wie sie behandelt werden, lesen Sie in dieser kurzen Übersicht.
Literatur
1.
Zurück zum Zitat Said J et al. Lymphomas associated with HIV infection. In: Swerdlow SH et al. (Hrsg). WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th Edition). 2017:449-452. IARC Press: Lyon Said J et al. Lymphomas associated with HIV infection. In: Swerdlow SH et al. (Hrsg). WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th Edition). 2017:449-452. IARC Press: Lyon
2.
Zurück zum Zitat Hernández-Ramírez RU et al. Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. Lancet HIV. 2019;6(4):e240-9 Hernández-Ramírez RU et al. Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. Lancet HIV. 2019;6(4):e240-9
3.
Zurück zum Zitat Hoffmann C et al. CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma. AIDS. 2016;30(5):753-60 Hoffmann C et al. CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma. AIDS. 2016;30(5):753-60
4.
Zurück zum Zitat Hentrich M, Barta SK (Hrsg). HIV-associated hematological malignancies. 2016. Springer: Cham Heidelberg New York Dordrecht London Hentrich M, Barta SK (Hrsg). HIV-associated hematological malignancies. 2016. Springer: Cham Heidelberg New York Dordrecht London
5.
Zurück zum Zitat Schommers P et al. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. Br J Haematol. 2015;168(6):806-10 Schommers P et al. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. Br J Haematol. 2015;168(6):806-10
6.
Zurück zum Zitat Ramos JC et al. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood. 2020;136(11):1284-97 Ramos JC et al. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood. 2020;136(11):1284-97
7.
Zurück zum Zitat Bartlett NL et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-9 Bartlett NL et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-9
8.
Zurück zum Zitat Roschewski M et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J Clin Oncol. 2020;38(22):2519-29 Roschewski M et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J Clin Oncol. 2020;38(22):2519-29
9.
Zurück zum Zitat Alderuccio JP et al. HIV-associated Burkitt ymphoma: outcomes from a US-UK collaborative analysis. Blood Adv. 2021;5(14):2852-62 Alderuccio JP et al. HIV-associated Burkitt ymphoma: outcomes from a US-UK collaborative analysis. Blood Adv. 2021;5(14):2852-62
10.
Zurück zum Zitat Castillo JJ et al. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019;184(4):679-82 Castillo JJ et al. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019;184(4):679-82
11.
Zurück zum Zitat Hentrich M et al. Characteristics and outcome of Human deficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study. Br J Haematol. 2021;194(3):642-6 Hentrich M et al. Characteristics and outcome of Human deficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study. Br J Haematol. 2021;194(3):642-6
12.
Zurück zum Zitat Lurain K et al. Viral, immunologic, and clinical features of primary effusion lymphoma. Blood. 2019;133(16):1753-61 Lurain K et al. Viral, immunologic, and clinical features of primary effusion lymphoma. Blood. 2019;133(16):1753-61
13.
Zurück zum Zitat Gupta NK et al. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol. 2017;19(1):99-108 Gupta NK et al. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol. 2017;19(1):99-108
14.
Zurück zum Zitat Lurain K et al. Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. Blood. 2020;136(19):2229-32 Lurain K et al. Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. Blood. 2020;136(19):2229-32
15.
Zurück zum Zitat Hentrich M et al. Stage-adapted treatment of human immunodeficiency virus associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30(33):4117-23 Hentrich M et al. Stage-adapted treatment of human immunodeficiency virus associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30(33):4117-23
16.
Zurück zum Zitat Hentrich M et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: long-term results of a prospective multi-institutional study. DGHO. 2021;Abstr V634 Hentrich M et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: long-term results of a prospective multi-institutional study. DGHO. 2021;Abstr V634
17.
Zurück zum Zitat Schommers P et al. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 2018;103(5):857-64 Schommers P et al. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 2018;103(5):857-64
18.
Zurück zum Zitat Hübel K et al. Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2019;54(10):1625-31 Hübel K et al. Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2019;54(10):1625-31
19.
Zurück zum Zitat Allred J et al. Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations. Bone Marrow Transplant. 2021;56(3):679-82 Allred J et al. Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations. Bone Marrow Transplant. 2021;56(3):679-82
20.
Zurück zum Zitat Hentrich M et al. Maligne Lymphome im Rahmen der HIV-Erkrankung und Posttransplantationslymphome. In: Dreyling M (Hg). Manual Maligne Lymphome. 2019: 251-65; Tumorzentrum München, Zuckschwerdt Verlag: München Hentrich M et al. Maligne Lymphome im Rahmen der HIV-Erkrankung und Posttransplantationslymphome. In: Dreyling M (Hg). Manual Maligne Lymphome. 2019: 251-65; Tumorzentrum München, Zuckschwerdt Verlag: München
Metadaten
Titel
Schwerpunkt "HIV-assoziierte Tumoren"
HIV-assoziierte Lymphome
verfasst von
Prof. Dr. med. Marcus Hentrich
Publikationsdatum
15.11.2021
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 11/2021
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-021-8845-x

Weitere Artikel der Ausgabe 11/2021

InFo Hämatologie + Onkologie 11/2021 Zur Ausgabe

Journal club

kurz notiert

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.